Recent 8-K filings for MRKR
Highest-materiality recent filing
Marker Therapeutics stockholders approve issuance of 8.28M warrant shares
- At special meeting on March 21, 2025, 4,158,543 shares (38.83% of outstanding) represented.
- Proposal passed: 3,483,897 for, 668,383 against, 6,263 abstained.
-
Marker Therapeutics shareholders approve increase in authorized shares from 30M to 130M
Shareholders approved Charter Amendment to increase authorized common stock from 30M to 130M shares (10.9M for, 1.4M against).
-
Marker Therapeutics reports Q3 net loss $2.0M; APOLLO study shows 66% ORR, 50% CR in NHL
Cash $17.6M + restricted $1.4M; runway into Q3 2026; raised ~$10M via ATM.
-
Marker Therapeutics Phase 1 APOLLO data: 66% ORR in NHL; 50% CR; dose expansion cleared
66% objective response rate in NHL patients (8/12), with 50% complete response (6/12) at doses 100-200×10^6 cells.
-
Marker partners Cellipont for cGMP manufacturing of MT-601 for lymphoma trial
Partnered with Cellipont Bioservices for cGMP manufacturing of MT-601, a MAR-T cell therapy for lymphoma in Phase 1 APOLLO study.
-
Marker Therapeutics: lymphodepletion improves MT-601 cell expansion; enrollment surging
Phase 1 APOLLO study data: TCR sequencing shows MT-601 clones expanded/persisted at higher levels with lymphodepletion.
-
Marker Therapeutics FY2024 net loss $10.7M; MT-601 78% response rate in lymphoma
Net loss of $10.7M for FY2024 vs $8.2M in FY2023; R&D expense $13.5M, G&A $4.2M.
-
Marker Therapeutics stockholders approve issuance of 8.28M warrant shares
At special meeting on March 21, 2025, 4,158,543 shares (38.83% of outstanding) represented.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.55 · Most common event other_material